interestingly COAST reports ph3 first in early Q2 2025 which is trial with eyelea - eyelea has $6B+ in sales and from memory OPT p2b in comparison to eyelea was better result than against lucentis (which only does about $1.5B of sales p.a)
So all in all - it’s the first trial result which will make or break this company
Ann: Security Class Reinstatement to Quotation- OPTOB, page-18
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.5¢ |
Change
-0.010(1.24%) |
Mkt cap ! $978.7M | |||
| Open | High | Low | Value | Volume |
| 81.0¢ | 81.0¢ | 78.8¢ | $1.042M | 1.308M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1823 | 79.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.0¢ | 22000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |